anti glp 1 drugs GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care Semaglutide vs. Other GLP-1 Receptor

As the global demand for GLP-1 drugs continues to grow, LC-MS characterization will remain a key component of regulatory compliance, biosimilar comparison, and pharmaceutical quality assurance

GLP-1 medications begin working at the molecular level within hours, activating receptors in the brain and gut

doi: 10.1186/s12933-022-01474-z Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Citation Ferhatbegovi L, Mri D and Maci-Dankovi A (2023) The benefits of GLP1 receptors in cardiovascular diseases

PMID: 36566341

The following history attempts to correct the traditional narrative by capturing some of the women's voices and the many different roles they played alongside male colleagues in shaping the development of GLP-1 drugs